(544 days)
Not Found
No
The summary describes a system for reprocessing dialyzers using a patented two-phase cleaning process and includes hardware and software for tracking and record-keeping. There is no mention of AI or ML capabilities in the description of the device's function or performance studies.
No
The device is a reprocessing system for dialyzers, not a device that directly treats a patient. It cleans and prepares dialyzers for reuse, which are then used in a therapeutic procedure (dialysis).
No
Explanation: The ClearFlux™ Dialyzer Reprocessing System is indicated for reprocessing and tracking dialyzers, not for diagnosing medical conditions in patients. It performs functional tests on dialyzers (e.g., volume and leak testing) to ensure their suitability for reuse, but these are quality control measures for a device, not diagnostic tests for human health.
No
The device description explicitly states that the ClearFlux™ Dialyzer Reprocessing System includes both hardware and software components, listing several specific hardware components like the ClearFlux™ Machine(s), System Computer, wireless hub, bar code reader, label printer, report printer, and air compressor.
Based on the provided text, the ClearFlux™ Dialyzer Reprocessing System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is to reprocess and track dialyzers used in hemodialysis. This is a process performed on a medical device (the dialyzer) to prepare it for reuse in a patient's treatment. It does not involve testing a sample taken from the human body to provide information about a physiological state, disease, or condition.
- Device Description: The description details hardware and software for cleaning, disinfecting, testing, and tracking dialyzers. It mentions chemicals used for cleaning and disinfection of the dialyzer and the system itself.
- Performance Studies: The performance studies focus on the effectiveness of the reprocessing process on the dialyzer itself (recovering volume and clearance, lack of adverse effects on the dialyzer). They do not involve evaluating the device's ability to diagnose or provide information about a patient's health status.
- Key Metrics: The key metrics measured (TCV, Leak Rate, Ultrafiltration, Clearance) are related to the performance and integrity of the dialyzer after reprocessing, not to a diagnostic measurement from a patient sample.
- Predicate Devices: The predicate devices listed are other dialyzer reprocessing systems, which are also not IVD devices.
In summary, the ClearFlux™ Dialyzer Reprocessing System is a device used to prepare another medical device (a dialyzer) for use in a medical procedure (hemodialysis). It does not perform diagnostic testing on patient samples.
N/A
Intended Use / Indications for Use
The ClearFlux™ Dialyzer Reprocessing System is indicated for the in vitro cleaning and disinfection of reusable polysulfone-based high-flux dialyzers, the recovery of the total cell volume (TCV) of the dialyzers, and the recovery of the small and middle molecules clearance of the dialyzers after processing. The ClearFlux™ Dialyzer Reprocessing System preprocesses polysulfone-based high-flux dialyzers prior to their first use. The ClearFlux™ Dialyzer Reprocessing System is indicated to be used only with the ClearFlux Formula™ cleaning solution. The ClearFlux™ Dialyzer Reprocessing System tracks and maintains dialyzer reprocessing operations, as well as dialyzer assignments to patients, and dialyzer reprocessing and reuse.
The ClearFlux™ Dialyzer Reprocessing System is indicated for the reprocessing of polysulfone-based high-flux dialyzers for reuse, for preprocessing the dialyzers prior to their assignment to patients for first use, and for tracking the reprocessed dialyzer for use only by the patient to whom the dialyzer was initially assigned. The steps used in reprocessing hemodialyzers with the ClearFlux™ System include: (1) pre-cleaning, (2) cleaning, (3) rinsing, (4) volume and leak testing, and (5) disinfecting the dialyzers in accordance with the "AAMI Recommended Practice for Reuse of Hemodialyzers." The ClearFlux™ System performs the patented in-situ two-phase cleaning cycle during reprocessing, which recovers the total cell volume and the clearance of small and middle molecules of the dialyzers to levels that are approximately equivalent to those of new dialyzers. The ClearFlux™ Dialyzer Reprocessing System is also indicated for performing record keeping of the dialyzer processing operation. The ClearFlux™ Dialyzer Reprocessing System is indicated to be used only with the ClearFlux Formula™ cleaning solution.
Product codes (comma separated list FDA assigned to the subject device)
LIF
Device Description
The ClearFlux™ Dialyzer Reprocessing System includes hardware and software designed to preprocess dialyzers before their first use by patients, to assign preprocessed dialyzers to patients, and to reprocess the dialyzer for reuse by the same patient to whom the dialyzer was originally assigned. The ClearFlux™ System employs the Novaflux patented two-phase flow cleaning process which is to be used only with the ClearFlux Formula™ (Cleaning Solution) in reprocessing reusable polysulfone-based high-flux dialyzers, and recovers the total cell volume (TCV) and the clearance of small and middle molecules of the dialyzers to levels that are approximately equivalent to those of new dialyzers.
The ClearFlux™ Dialyzer Reprocessing System consists of the following hardware and software components: the ClearFlux™ Machine(s), which performs the actual processing of the dialyzer; the ClearFlux™ Records Management System (CRMS), a patient-dialyzer tracking software loaded onto a System Computer to manage dialyzer reprocessing and reuse; a System Computer; a wireless hub for communication between the ClearFlux™ Machine(s) and the CRMS on the System Computer; a bar code reader to maintain identification of the dialyzers, the ClearFlux™ Machine(s), and the users of the System (e.g., technicians, administrators); a label printer to print the labels for the dialyzers, as well as to print the bar codes for the dialyzers. the users, and the ClearFlux™ Machine(s); a report printer; and an oil-less air compressor with a HEPA filter to provide the filtered airflow necessary for the operation of the ClearFlux™ Machine(s). The ClearFlux™ Dialyzer Reprocessing System (with one System Computer loaded with the CRMS software) can operate and track the dialyzer reprocessing operations of up to 12 ClearFlux™ Machines.
The chemicals used by the ClearFlux™ System include: Peracetic Acid Disinfectant used in the preprocessing and reprocessing of the dialyzers and in the daily and weekly disinfection of the fluid pathways of the ClearFlux™ Machine(s); the ClearFlux Formula™, a proprietary cleaning solution used exclusively in the ClearFlux™ Dialyzer Reprocessing System and in the weekly cleaning of the fluid pathways of the ClearFlux™ Machine(s); and optionally, Formula 409 NF for the weekly cleaning of the fluid pathways of the ClearFlux™ Machine(s).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical Performance Studies: Test results confirm that the patented ClearFlux™ two-phase flow process recovers the TCV and the clearance of small and middle molecules of reusable polysulfone-based high-flux dialvzers to levels that are approximately equivalent to those of new dialyzers, and that the ClearFlux™ process does not cause adverse effects on the dialyzers. The tests include: Cytotoxicity, Scanning Electron Microscopy, X-Ray Photoelectron Spectroscopy, Size Exclusion Chromatography, Total Cell Volume, Complement Activation, Albumin Loss, Clearance of Small Molecules, Clearance of Middle Molecules, Hydraulic Permeability and Pressure Leak. The results from these tests support the effectiveness of the ClearFlux™ System, as indicated.
Summary: Novaflux Technologies has performed in vitro and functional tests to show that the ClearFlux™ Dialyzer Reprocessing System does not have adverse effects on polysulfone-based high-flux dialyzers processed with the patented two-phase flow cleaning process, and that the ClearFlux™ System recovers the TCV and the clearance of small and middle molecules to levels that are approximately equivalent to those of new dialyzers.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K860674, K914580, K931336, K904210, K024076, K834447
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5820 Hemodialysis system and accessories.
(a)
Identification. A hemodialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and that consists of an extracorporeal blood system, a conventional dialyzer, a dialysate delivery system, and accessories. Blood from a patient flows through the tubing of the extracorporeal blood system and accessories to the blood compartment of the dialyzer, then returns through further tubing of the extracorporeal blood system to the patient. The dialyzer has two compartments that are separated by a semipermeable membrane. While the blood is in the blood compartment, undesirable substances in the blood pass through the semipermeable membrane into the dialysate in the dialysate compartment. The dialysate delivery system controls and monitors the dialysate circulating through the dialysate compartment of the dialyzer.(1) The extracorporeal blood system and accessories consists of tubing, pumps, pressure monitors, air foam or bubble detectors, and alarms to keep blood moving safely from the blood access device and accessories for hemodialysis (§ 876.5540) to the blood compartment of the dialyzer and back to the patient.
(2) The conventional dialyzer allows a transfer of water and solutes between the blood and the dialysate through the semipermeable membrane. The semipermeable membrane of the conventional dialyzer has a sufficiently low permeability to water that an ultrafiltration controller is not required to prevent excessive loss of water from the patient's blood. This conventional dialyzer does not include hemodialyzers with the disposable inserts (Kiil type) (§ 876.5830) or dialyzers of high permeability (§ 876.5860).
(3) The dialysate delivery system consists of mechanisms that monitor and control the temperature, conductivity, flow rate, and pressure of the dialysate and circulates dialysate through the dialysate compartment of the dialyzer. The dialysate delivery system includes the dialysate concentrate for hemodialysis (liquid or powder) and alarms to indicate abnormal dialysate conditions. This dialysate delivery system does not include the sorbent regenerated dialysate delivery system for hemodialysis (§ 876.5600), the dialysate delivery system of the peritoneal dialysis system and accessories (§ 876.5630), or the controlled dialysate delivery system of the high permeability hemodialysis system § 876.5860).
(4) Remote accessories to the hemodialysis system include the unpowered dialysis chair without a scale, the powered dialysis chair without a scale, the dialyzer holder set, dialysis tie gun and ties, and hemodialysis start/stop tray.
(b)
Classification. (1) Class II (performance standards) for hemodialysis systems and all accessories directly associated with the extracorporeal blood system and the dialysate delivery system.(2) Class I for other accessories of the hemodialysis system remote from the extracorporeal blood system and the dialysate delivery system, such as the unpowered dialysis chair, hemodialysis start/stop tray, dialyzer holder set, and dialysis tie gun and ties. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
K091360
Page 1 of 3
NOV - 3 2010
510(k) Summary Submitted in Accordance with 21 CFR 807.92
| 510(k) Submitted: | Novaflux Technologies
1 Wall Street
Princeton, New Jersey 08540 |
|------------------------|-----------------------------------------------------------------------|
| Telephone: | (609) 683-0215 |
| Fax: | (609) 683-5003 |
| Contact Person: | Mohamed E. Labib, Ph.D.
President and CEO |
| Date Summary Prepared: | April 26, 2010 |
| Trade Name: | ClearFlux™ Dialyzer Reprocessing System |
| Common Name: | Dialyzer Reprocessing System |
| Device Classification: | Dialyzer Reprocessing System, Product Code LIF |
Device Description: The ClearFlux™ Dialyzer Reprocessing System includes hardware and software designed to preprocess dialyzers before their first use by patients, to assign preprocessed dialyzers to patients, and to reprocess the dialyzer for reuse by the same patient to whom the dialyzer was originally assigned. The ClearFlux™ System employs the Novaflux patented two-phase flow cleaning process which is to be used only with the ClearFlux Formula™ (Cleaning Solution) in reprocessing reusable polysulfone-based high-flux dialyzers, and recovers the total cell volume (TCV) and the clearance of small and middle molecules of the dialyzers to levels that are approximately equivalent to those of new dialyzers.
Panel 78 - unclassified
The ClearFlux™ Dialyzer Reprocessing System consists of the following hardware and software components: the ClearFlux™ Machine(s), which performs the actual processing of the dialyzer; the ClearFlux™ Records Management System (CRMS), a patient-dialyzer tracking software loaded onto a System Computer to manage dialyzer reprocessing and reuse; a System Computer; a wireless hub for communication between the ClearFlux™ Machine(s) and the CRMS on the System Computer; a bar code reader to maintain identification of the dialyzers, the ClearFlux™ Machine(s), and the users of the System (e.g., technicians, administrators); a label printer to print the labels for the dialyzers, as well as to print the bar codes for the dialyzers. the users, and the ClearFlux™ Machine(s); a report printer; and an oil-less air compressor with a HEPA filter to provide the filtered airflow necessary for the operation of the ClearFlux™ Machine(s). The ClearFlux™ Dialyzer Reprocessing System (with one System Computer loaded with the CRMS
1
software) can operate and track the dialyzer reprocessing operations of up to 12 ClearFlux™ Machines.
The chemicals used by the ClearFlux™ System include: Peracetic Acid Disinfectant used in the preprocessing and reprocessing of the dialyzers and in the daily and weekly disinfection of the fluid pathways of the ClearFlux™ Machine(s); the ClearFlux Formula™, a proprietary cleaning solution used exclusively in the ClearFlux™ Dialyzer Reprocessing System and in the weekly cleaning of the fluid pathways of the ClearFlux™ Machine(s); and optionally, Formula 409 NF for the weekly cleaning of the fluid pathways of the ClearFlux™ Machine(s).
Intended Use: The ClearFlux™ Dialyzer Reprocessing System is indicated for the in vitro cleaning and disinfection of reusable polysulfone-based high-flux dialyzers, the recovery of the total cell volume (TCV) of the dialyzers, and the recovery of the small and middle molecules clearance of the dialyzers after processing. The ClearFlux™ Dialyzer Reprocessing System preprocesses polysulfone-based high-flux dialyzers prior to their first use. The ClearFlux™ Dialyzer Reprocessing System is indicated to be used only with the ClearFlux Formula™ cleaning solution. The ClearFlux™ Dialyzer Reprocessing System tracks and maintains dialyzer reprocessing operations, as well as dialyzer assignments to patients, and dialyzer reprocessing and reuse.
Substantially Equivalent Devices:
- K860674, K914580, K931336, DRS-4® Dialyzer Reprocessing System, Seratronics, Inc.
Agents: Disinfectant - Peracetic Acid
Cleaning solutions - Bleach
Measures: TCV, Leak Rate (pressure decay), Ultrafiltration
- K904210, Renatron II® Dialyzer Reprocessing System, Minntech Corp.
- Agents: Peracetic Acid cleaning solution and disinfectant, Formula 409 NF machine cleaner
Measures: TCV, Leak Rate (negative pressure leak)
- K024076, Maky® 21.1 Dialyzer Reprocessing System, HDC Maquinolas, LLC Agents: "any acceptable cleaning agent" including bleach or peracetic
- acid; "any choice of acceptable germicides" including bleach, peracetic acid, formaldehyde and glutaraldehyde
Measures: TCV, Leak Rate (pressure decay)
Process: "The aggressive agitation process is a result of a hydropneumatic design that combines high air pressure with a cleaning agent, forcing particles out of the dialyzer."
- K834447, ECHO MM-1000® Automated Dialyzer Reprocessor, Mesa Laboratories, Inc.
- Agents: Disinfectants glutaraldehyde, formaldehyde, peracetic acid System cleaning - disinfectant, bleach
2
Measures: TCV, Leak Rate (pressure decay)
- Non-clinical Performance Studies: Test results confirm that the patented ClearFlux™ two-phase flow process recovers the TCV and the clearance of small and middle molecules of reusable polysulfone-based high-flux dialvzers to levels that are approximately equivalent to those of new dialyzers, and that the ClearFlux™ process does not cause adverse effects on the dialyzers. The tests include: Cytotoxicity, Scanning Electron Microscopy, X-Ray Photoelectron Spectroscopy, Size Exclusion Chromatography, Total Cell Volume, Complement Activation, Albumin Loss, Clearance of Small Molecules, Clearance of Middle Molecules, Hydraulic Permeability and Pressure Leak. The results from these tests support the effectiveness of the ClearFlux™ System, as indicated.
- Summary: Novaflux Technologies has performed in vitro and functional tests to show that the ClearFlux™ Dialyzer Reprocessing System does not have adverse effects on polysulfone-based high-flux dialyzers processed with the patented two-phase flow cleaning process, and that the ClearFlux™ System recovers the TCV and the clearance of small and middle molecules to levels that are approximately equivalent to those of new dialyzers.
- Conclusion: The information provided in the 510(k) supports the claim that the ClearFlux™ Dialyzer Reprocessing System is substantially equivalent to legally marketed predicate devices for the intended use in reprocessing polysulfone-based high-flux dialyzers for reuse.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is a circular emblem with the department's name surrounding an abstract symbol. The symbol appears to be an stylized image of people.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Mohamed E. Labib, Ph.D. President and CEO Novaflux Technologies I Wall Street PRINCETON NJ 08540
3 2010 NOV
Re: K091360
Trade/Device Name: ClearFlux™ Dialyzer Reprocessing System Regulation Number: None Regulatory Class: Unclassified Product Code: LIF Dated: September 17, 2010 Received: September 20, 2010
Dear Dr. Labib:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related
4
Page 2
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Michael Lemur MD
Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known): K091360
Device Name: ClearFlux™ Dialyzer Reprocessing System
Indications for Use:
The ClearFlux™ Dialyzer Reprocessing System is indicated for the reprocessing of polysulfone-based high-flux dialyzers for reuse, for preprocessing the dialyzers prior to their assignment to patients for first use, and for tracking the reprocessed dialyzer for use only by the patient to whom the dialyzer was initially assigned. The steps used in reprocessing hemodialyzers with the ClearFlux™ System include: (1) pre-cleaning, (2) cleaning, (3) rinsing, (4) volume and leak testing, and (5) disinfecting the dialyzers in accordance with the "AAMI Recommended Practice for Reuse of Hemodialyzers." The ClearFlux™ System performs the patented in-situ two-phase cleaning cycle during reprocessing, which recovers the total cell volume and the clearance of small and middle molecules of the dialyzers to levels that are approximately equivalent to those of new dialyzers. The ClearFlux™ Dialyzer Reprocessing System is also indicated for performing record keeping of the dialyzer processing operation. The ClearFlux™ Dialyzer Reprocessing System is indicated to be used only with the ClearFlux Formula™ cleaning solution.
Prescription Use ____________________________________________________________________________________________________________________________________________________________
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division Sign-O ivision of Reproduc · ((k) Number
Page_1 of 1